Campbell & CO Investment Adviser LLC bought a new stake in AtriCure Inc. (NASDAQ:ATRC) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,254 shares of the medical device company’s stock, valued at approximately $366,000.
Other institutional investors have also recently bought and sold shares of the company. Macquarie Group Ltd. boosted its stake in shares of AtriCure by 1.0% during the 4th quarter. Macquarie Group Ltd. now owns 65,786 shares of the medical device company’s stock worth $2,013,000 after acquiring an additional 681 shares in the last quarter. Quantum Capital Management increased its holdings in shares of AtriCure by 0.7% during the 1st quarter. Quantum Capital Management now owns 127,035 shares of the medical device company’s stock worth $3,403,000 after buying an additional 845 shares during the last quarter. Bell Rock Capital LLC acquired a new stake in AtriCure in the 1st quarter valued at $26,000. Rhumbline Advisers increased its holdings in AtriCure by 3.4% in the 1st quarter. Rhumbline Advisers now owns 48,738 shares of the medical device company’s stock valued at $1,306,000 after purchasing an additional 1,594 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in AtriCure by 31.0% in the 4th quarter. Legal & General Group Plc now owns 6,958 shares of the medical device company’s stock valued at $213,000 after purchasing an additional 1,646 shares in the last quarter. 89.20% of the stock is owned by institutional investors and hedge funds.
Several brokerages have recently weighed in on ATRC. ValuEngine downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 19th. JPMorgan Chase & Co. began coverage on shares of AtriCure in a research report on Friday, April 12th. They set an “overweight” rating and a $37.00 price target on the stock. Zacks Investment Research cut shares of AtriCure from a “buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. BidaskClub raised shares of AtriCure from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 26th. Finally, Northland Securities reissued a “buy” rating on shares of AtriCure in a report on Friday, April 26th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $37.20.
In other AtriCure news, SVP Justin J. Noznesky sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the sale, the senior vice president now owns 94,068 shares of the company’s stock, valued at $2,822,040. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael H. Carrel sold 25,000 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $32.00, for a total transaction of $800,000.00. Following the completion of the sale, the chief executive officer now owns 661,103 shares of the company’s stock, valued at approximately $21,155,296. The disclosure for this sale can be found here. Insiders sold a total of 37,158 shares of company stock worth $1,169,102 in the last quarter. Insiders own 8.00% of the company’s stock.
Shares of NASDAQ:ATRC opened at $31.31 on Friday. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -33.31 and a beta of 0.24. AtriCure Inc. has a 12-month low of $26.11 and a 12-month high of $36.49. The company has a quick ratio of 3.10, a current ratio of 3.72 and a debt-to-equity ratio of 0.15. The firm’s fifty day moving average is $31.08.
AtriCure (NASDAQ:ATRC) last announced its earnings results on Tuesday, July 30th. The medical device company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.01. The firm had revenue of $58.90 million for the quarter, compared to the consensus estimate of $57.76 million. AtriCure had a negative net margin of 9.46% and a negative return on equity of 13.06%. The business’s quarterly revenue was up 13.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.19) EPS. Sell-side analysts expect that AtriCure Inc. will post -0.78 earnings per share for the current year.
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.
Further Reading: Google Finance Portfolio Workaround
Receive News & Ratings for AtriCure Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AtriCure and related companies with MarketBeat.com’s FREE daily email newsletter.